E10A is a novel anti-tumor gene therapy based on recombinant human endostatin adenovirus technology, designed to inhibit tumor angiogenesis. As the first gene therapy product in China to complete Phase III clinical trials, it has also obtained US FDA SPA (Special Protocol Assessment) clearance.
E10A®
Recombinant human endostatin adenovirus injection
Developed by Doublle Biotech · Anti-tumor gene therapy
National Class I New Drug Gene Therapy Drug China Patent Gold Award US FDA SPA
🏆 First in China to enter and complete Phase III gene therapy trials
🇺🇸 US Phase III granted SPA (Special Protocol Assessment)
📜 National Major New Drug programs: 11th, 12th, 13th Five-Year plans
🏝️ Boao Hainan Biomedical New Technology Transformation Project
🥇 Gold Award – 12th China Patent Award (core patent)
🔬 Indication: Head and neck tumors (excluding nasopharyngeal cancer)
📞 Contact US · Inquiry
